Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 18, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...

- Phase II results showed statistically significant pain relief through 24 weeks- Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI,...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 06, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 15, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...